Romiplostim for the treatment of chronic immune thrombocytopenia

  • Technology appraisal guidance
  • TA221
  • Published: 
  • Last updated: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by the Aberdeen Health Technology Assessment Group:

  • Mowatt G, Boachie C, Crowther M et al., Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura (ITP): a single technology appraisal, December 2008

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist, patient or carer groups, and other consultees had the opportunity to give their expert views. Manufacturers or sponsors, professional or specialist, patient or carer groups, and other consultees also have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Amgen

Professional or specialist, and patient or carer groups:

  • British Committee for Standards in Haematology

  • British Society for Haematology

  • ITP Support Association

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

Other consultees:

  • Department of Health

  • Eastern and Coastal Kent Teaching Primary Care Trust

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Actavis UK

  • Baxter BioScience

  • Bio Products Laboratory

  • CSL Behring

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Focus Pharmaceuticals

  • GlaxoSmithKline UK

  • NHS Quality Improvement Scotland

  • Pharmacia

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on romiplostim for the treatment of chronic immune thrombocytopenia by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Paula Bolton-Maggs, Consultant Haematologist, Manchester Royal Infirmary, nominated by the Royal College of Pathologists and the British Committee for Standards in Haematology – clinical specialist

  • Dr Nichola Cooper, Consultant Haematologist, Hammersmith Hospital, nominated by the ITP Support Association – clinical specialist

  • Dr John Grainger, Consultant Paediatric Haematologist, Royal Manchester Children's Hospital, nominated by the ITP Support Association – clinical specialist

  • Dr Jennie Wimperis, Consultant Haematologist, Norfolk and Norwich University Hospital, nominated by the ITP Support Association – clinical specialist

  • Mrs Shirley Watson, Chief Executive, ITP Support Association, nominated by the ITP Support Association – patient expert

  • Mr Derek Elston, nominated by the ITP Support Association – patient expert

Representatives from the following manufacturer or sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Amgen